Teladoc (TDOC) Expected to Beat Earnings Estimates: Should You Buy?
Teladoc (TDOC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Stock Drops Despite Market Gains: Important Facts to Note
Teladoc (TDOC) concluded the recent trading session at $8.57, signifying a -4.88% move from its prior day's close.
All You Need to Know About Teladoc (TDOC) Rating Upgrade to Buy
Teladoc (TDOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Strength Seen in Teladoc (TDOC): Can Its 6.3% Jump Turn into More Strength?
Teladoc (TDOC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Teladoc Health Q2 Loss Narrower Than Expected on Declining Expenses
TDOC posts narrower Q2 loss and trims costs, but shares dip as U.S. revenues and visit volumes decline.
Teladoc Health: Still Struggling To Find A Catalyst
Teladoc Health remains a deep value play at $7, trading at just 5-6x EBITDA, but lacks a clear growth catalyst. Revenue and user metrics are declining across core segments, with BetterHelp and Chronic Care both losing momentum and failing to innovate. Recent acquisitions (UpLift, Catapult Health) have not meaningfully expanded Teladoc's platform or addressed its reliance on basic telehealth connections.
Teladoc Health Earnings: Not Dead Yet
Teladoc's Q2 2025 earnings reaffirm strong free cash flow guidance, with the potential to reach $220 million in the next twelve months. Despite an attractive 7x next year's free cash flow valuation, revenue growth remains stagnant and threatens the bull case. Profitability and an improving balance sheet keep me tepidly bullish, but lack of growth and competitive pressures are major risks.
Teladoc Health, Inc. (TDOC) Q2 2025 Earnings Call Transcript
Teladoc Health, Inc. Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Charles Divita - CEO & Director Mala Murthy - Chief Financial Officer Michael Minchak - Vice President of Investor Relations Conference Call Participants Sarah Elizabeth James - Cantor Fitzgerald & Co., Research Division Charles Rhyee - TD Cowen, Research Division Daniel R. Grosslight - Citigroup Inc., Research Division David Harrison Roman - Goldman Sachs Group, Inc., Research Division Elizabeth Hammell Anderson - Evercore ISI Institutional Equities, Research Division Jailendra P.
Teladoc (TDOC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Teladoc (TDOC) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Teladoc (TDOC) Reports Q2 Loss, Beats Revenue Estimates
Teladoc (TDOC) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.28 per share a year ago.
Teladoc (TDOC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc Health: A Beaten-Down Bargain Worth A Second Look (Upgrade)
I've upgraded Teladoc to a tepid buy—not a full conviction call, but the numbers finally tilt in its favor. I believe the company's innovative platform positions it as a leader in digital healthcare, driving long-term value. 7x forward free cash flow is just too low to ignore, even with weak top-line growth.
